Mira Pharmaceuticals (MIRA) Cash from Financing Activities (2022 - 2025)

Mira Pharmaceuticals has disclosed Cash from Financing Activities across 4 years of filings, most recently posting $4.8 million for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at $4.8 million, up 881.03% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.2 million (up 115.66% YoY), and the FY2025 annual result was $8.2 million, up 115.66% from the prior year.
• Cash from Financing Activities came in at $4.8 million for Q4 2025 at Mira Pharmaceuticals, up from $3.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $7.6 million in Q3 2023 to a low of -$230749.0 in Q4 2023.
• The 4-year median for Cash from Financing Activities is $680354.5 (2022), against an average of $1.6 million.
• Peak annual rise in Cash from Financing Activities reached 1024.27% in 2023, while the deepest fall reached 120.26% in 2023.
• Mira Pharmaceuticals' Cash from Financing Activities stood at $1.1 million in 2022, then slumped by 120.26% to -$230749.0 in 2023, then jumped by 313.83% to $493401.0 in 2024, then soared by 881.03% to $4.8 million in 2025.
• The last three Cash from Financing Activities figures came in at $4.8 million (Q4 2025), $3.0 million (Q3 2025), and $323841.0 (Q2 2025), per Business Quant data.